Background
==========

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, and ranks the third leading cause of cancer-related death \[[@B1]\]. Hepatectomy is considered the main curative treatment for HC with a 5-year survival of 23.8--54.8% as reported in the most recent series \[[@B2]-[@B5]\]. Tumor recurrence even after radical surgery affects 75-100% HC patients, accounting for the major cause of death of HC patients \[[@B6]\]. The development of appropriate strategies to prevent tumor recurrence is therefore critical for improving long-term outcomes of HC patients after surgical resection.

Transcatheter arterial chemoembolization (TACE), which induces tumor ischemic necrosis by arterial injection of chemotherapeutic drugs and embolizing agents, is recommended as the first-line palliative treatment for inoperable HCC in the 2005 practice guidelines issued by the American Association for the Study of Liver Diseases \[[@B7]\]. Some researchers believed that it may reduce the viability of HCC cells before surgery and reduce postoperative tumor recurrence \[[@B8]\]. Although several studies have demonstrated the survival benefits of preoperative TACE for patients with HCC \[[@B9],[@B10]\], others have failed to show any significant survival benefit \[[@B11]-[@B16]\]. Therefore, the role of preoperative TACE for HCC remains a contradictory issue. A recent review of three randomized controlled trials (RCTs) showed that preoperative TACE did not significantly improve survival \[[@B17]\]. However, their study only involved 257 participants, and therefore may not be convincing enough to confirm the effect conclusively \[[@B18]\]. To produce more reliable evidence for clinical decision-making, meta-analytic techniques could be applied to nonrandomized comparative studies (NRCTs) to ensure both the number and sample size of RCTs \[[@B19]\], knowing that meta-analysis of well-designed NRCTs is feasible and the results are remarkably similar to those of contemporaneous RCTs \[[@B20]\]. The present meta-analysis should be able to provide an updated evaluation on preoperative TACE for resectable HCC by taking into account all the currently evidence from RCTs and well-designed NRCTs.

Methods
=======

Inclusion and exclusion criteria
--------------------------------

The present meta-analysis was performed by following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. Primary studies that evaluated the efficacy of preoperative TACE vs. no-preoperative TACE for resectable HCC were considered for inclusion. For duplicate publications reported by the same authors, either the one of higher quality or the most recent publication was selected. Abstracts, letters, editorials and expert opinions, reviews without original data, case reports, and uncontrolled studies were excluded. Study populations including recurrent HCC or unresectable diseases were also excluded.

Study selection
---------------

A computerized search of the literature was performed by searching Medline, EMBASE, OVID, and Cochrane database from the time of inception to June 2012. The following medical subject heading (MeSH) terms were used: "hepatectomy," "hepatocellular carcinoma," and "transarterial chemoembolization". Only studies on humans and in the English language were considered for inclusion. Reference lists of all identified articles were manually searched for additional studies. Publication bias was assessed visually using a funnel plot.

Data extraction
---------------

Two reviewers (LW and YZ) independently extracted the following parameters from each study: first author, year of publication, study population characteristics, study design, inclusion and exclusion criteria, the number of subjects in each arm, survival, recurrence, morbidity and mortality. All relevant texts, tables and figures were reviewed for data extraction.

Qualitative analysis
--------------------

The RCTs were scored using the Jadad composite scale \[[@B21]\], which evaluates studies based on appropriate randomization, double blinding, and an adequate description of withdrawals and drop-outs. For evaluation of NRCTs, the methodological index for nonrandomized studies (MINORS) with some modifications were applied \[[@B22]\]. The following 12 items were evaluated for each study: a clearly stated aim, consecutive patients, prospective data collection, reported endpoints, unbiased outcome evaluation, adequate length of follow-up, loss to follow up \<5%, ≥ 20 patients in each arm, adequate control group, contemporary groups, controls equivalent to cases, and adequate statistical analyses. Studies achieving more than 16 points (maximum 24) were defined as well-designed and were included in the meta-analysis \[[@B20]\]. Those with less than 16 points were excluded.

Outcomes of interests
---------------------

Items for assessing long-term outcomes included disease-free and overall survival rate at 5 year, total recurrence, hepatic recurrence, and extrahepatic recurrence.

Items for assessing short-term outcomes included postoperative morbidity and in-hospital mortality.

Statistical analysis and synthesis
----------------------------------

Dichotomous variables were tested by odds ratio (OR) with a 95% confidence interval (95% CI), and continuous variables were tested by the weighted mean difference (WMD) with a 95% CI. Between-study heterogeneity was evaluated by *χ*^2^ and *I*^*2*^. Data that were not significantly heterogeneous *(P* \> 0.1) were calculated using a fixed effects model, and heterogeneous data (*P* \< 0.1) were calculated using a random-effects model. Sensitivity analysis was undertaken by using the following subgroups: (1) RCTs, (2) NRCTs, and (3) studies with matched clinicopathological parameters. Statistical analyses were performed with Review Manager version 5.0 (The Cochrane Collaboration, Software Update, Oxford). A value of *P* \< 0.05 was considered statistically significant.

Results
=======

Eligible studies
----------------

Twenty-six studies that matched the selection criteria were retrieved from the electronic databases \[[@B9]-[@B16],[@B23]-[@B41]\]. Of these studies, one study was excluded due to overlap of authors and nonrandomized nature \[[@B23]\], and therefore the most recent RCT was included \[[@B24]\]. Four NRCTs with fewer than 16 points were excluded \[[@B9],[@B25]-[@B27]\]. Finally, 21 articles, including four RCTs \[[@B14]-[@B16],[@B24]\] and 17 NRCTs \[[@B10]-[@B13],[@B28]-[@B40]\], met the inclusion criteria.

The characteristics of the 21 studies are summarized in Table [1](#T1){ref-type="table"}. A total of 3,210 patients were included in the meta-analysis, of whom 1,431 received preoperative TACE and 1,779 were allocated to a control group. The number of patients in each study varied from 40 to 350 patients. In the enrolled patients, the percentage of men ranged from 76.9% to 100% and the mean age ranged from 45.3 ± 9.8 to 68.1 ± 5.7 years. Eight studies were completely matched with respect to the reported clinicopathological parameters \[[@B12],[@B15],[@B16],[@B28],[@B30],[@B32],[@B35],[@B39]\]. One trial was conducted to compare outcomes of whole-liver TACE, selective TACE, and without preoperative TACE \[[@B24]\]. Only selective TACE arm was considered in the present meta-analysis.

###### 

Clinical background of studies included in the meta-analysis

  **Reference**          **Year**   **Inclusion Period**   **Country**    **Group**           **No. of patients**   **M/F**        **Mean age (years)**          **Mean AFP (ng/ml)**                  **Child-Pugh A/B/C**    **LB N/H/C**              **Tumor size (cm)**          **Matching**          **Not matching**   **Score**
  ---------------------- ---------- ---------------------- -------------- ------------------- --------------------- -------------- ----------------------------- ------------------------------------- ----------------------- ------------------------- ---------------------------- --------------------- ------------------ -----------
  **RCTs**                                                                                                                                                                                                                                                                                                                      
  Wu \[[@B14]\]          1995       1983-1991              Taiwan         TACE (+) TACE (−)   24 28                 23/1 23/5      51.8 ± 12.4 53.2 ± 11.5       ≥ 400 (n = 15) ≥ 400 (n = 16)         22/2/0 24/4/0           ---/---/14 ---/---/12     14.3 ± 4.2 14.5 ± 3.3        1-3,5-15              17                 2
  Yamasaki \[[@B15]\]    1996       1987-1989              Japan          TACE (+) TACE (−)   50 47                 50/0 47/0      54.9 ± 6.4 57.1 ± 4.9         --- ---                               --- ---                 ---/---/--- ---/---/---   3.1 ± 0.8 3.3 ± 0.9          1,2,4,9-12            ---                2
  Zhou \[[@B16]\]        2009       2001-2003              China          TACE (+) TACE (−)   52 56                 48/4 49/7      45.3 ± 9.8 46.8 ± 9.6         1244.2 ± 376 1387.5 ± 426             44/8/0 54/2/0           ---/---/49 ---/---/50     9.0 ± 3.2 9.5 ± 3.9          1-3,5-10, 12,14,15    ---                3
  Kaibori \[[@B24]\]     2012       2004-2007              Japan          TACE (+) TACE (−)   42 43                 35/7 32/11     68.1 ± 5.7 66.1 ± 10.6        2432 ± 11638 858 ± 5269               37/5/0 39/4/0           1/27/14 4/28/11           4.3 ± 2.1 4.8 ± 4.1          1-10,12, 13,15        11                 3
  **NRCTs**                                                                                                                                                                                                                                                                                                                     
  Nagasue \[[@B12]\]     1989       1980-1986              Japan          TACE (+) TACE (−)   31 107                25/6 90/17     56.5 ± 9.1 59.4 ± 8.9         \>20 (n = 18) \>20 (n = 76)           17/13/1 69/32/6         ---/---/26 ---/---/88     \>3 (n = 17) \>3 (n = 72)    1-3,5,6, 8--11,14     ---                19
  Adachi \[[@B13]\]      1993       1981-1991              Japan          TACE (+) TACE (−)   46 26                 39/7 21/5      55.9 ± 7.71 59.8 ± 5.7        \>20 (n = 24) \>20 (n = 15)           --- ---                 ---/---/29 ---/---/22     2.6 ± 0.9 2.1 ± 0.9          2-4,6-8,11,14,16      1,9,13             18
  Harada \[[@B28]\]      1996       1982-1994              Japan          TACE (+) TACE (−)   105 35                90/15 30/5     57.6 ± 9.7 59.8 ± 9.9         --- ---                               --- ---                 ---/---/69 ---/---/24     \>5 (n = 36) \>5 (n = 9)     1,2,4,7-10,12         ---                19
  Uchida \[[@B29]\]      1996       1986-1991              Japan          TACE (+) TACE (−)   60 68                 50/10 52/16    59.0 ± 9.9 62.0 ± 7.2         \>20 (n = 27) \>20 (n = 45)           37/18/5 45/18/5         ---/---/42 ---/---/49     3.7 ± 3.1 4.4 ± 3.4          2,4-10,14             1,3,11,13          18
  Majno \[[@B10]\]       1997       1985-1995              France         TACE (+) TACE (−)   49 27                 44/5 26/1      59.2 ± 7.1 60.9 ± 7.8         285 ± 1629 129 ± 250                  43/6/0 17/10/0          0/0/49 0/0/27             5.05 ± 2.5 3.9 ± 1.8         1-3,8,10, 12-14       5-7                18
  Di Carlo \[[@B11]\]    1998       1989-1997              Italy          TACE (+) TACE (−)   55 45                 49/6 34/11     63.0 ± 6.0 62.0 ± 6.0         \>10 (n = 13) \>100 (n = 6)           48/---/--- 36/---/---   0/0/55 0/0/45             \>3 (n = 32) \>3 (n = 31)    1-3,5,7-12,14,15      13                 18
  Paye \[[@B30]\]        1998       1986-1992              France         TACE (+) TACE (−)   24 24                 21/3 17/7      57 ± 2 54 ± 3                 2560 (2--46000) 4229 (2--73000)       22/2 22/2               1/---/13 1/---/13         7.8 ± 1 7.3 ± 1              1-3,5-10,12-14,16     ---                17
  Lu \[[@B31]\]          1999       1988-1994              China, Japan   TACE (+) TACE (−)   44 76                 36/8 57/19     51.5 54.5                     --- ---                               31/13/0 61/15/0         ---/---/28 ---/---/44     7.3 7.6                      2,5,6,8,9,11,14       1                  20
  Ochiai \[[@B32]\]      2003       1978-1994              Japan          TACE (+) TACE (−)   100 48                78/22 43/5     59.6 ± 8 58.9 ± 8.7           \>400 (n = 74) \>400 (n = 30)         --- ---                 ---/---/--- ---/---/---   4.4 ± 3.3 4.4 ± 3.1          1-4,6,7,9, 10,12-15   ---                20
  Sugo \[[@B33]\]        2003       1997-2000              Japan          TACE (+) TACE (−)   146 81                122/24 67/14   57.6 ± 9.4 60.5 ± 9           --- ---                               118/27/1 74/6/1         ---/---/116 ---/---/58    4.5 ± 3.0 4.8 ± 3.9          2,5,8,9               1                  18
  Sasaki \[[@B34]\]      2006       1982-2003              Japan          TACE (+) TACE (−)   109 126               85/24 97/29    \>65 (n = 38) \>65 (n = 68)   \>100 (n = 40) \>100 (n = 49)         --- ---                 ---/---/76 ---/---/61     ≥5 (n = 27) ≥5 (n = 47)      2-4,7,9,11, 12        1,8                20
  Chen \[[@B35]\]        2007       1990-2004              China          TACE (+) TACE (−)   89 157                71/18 136/21   45.5 ± 6.3 48.6 ± 5.7         2838 ± 1721 2335 ± 1088               78/11/0 142/15/0        ---/---/15 ---/---/25     9.5 ± 2.6 9.9 ± 3.1          1-3,6-10,12,13,16     ---                20
  Choi \[[@B36]\]        2007       1998-2005              Korea          TACE (+) TACE (−)   120 153               93/27 117/36   52.4 ± 9.6 52.4 ± 10.4        8094 ± 68967 2292 ± 7444              117/0/0 150/2/0         ---/---/56 ---/---/75     \>5 (n = 44) \>5 (n = 50)    1-6,8-10,12-14        7                  19
  Kim \[[@B37]\]         2008       1995-2000              Korea          TACE (+) TACE (−)   97 237                80/17 194/43   48.8 ± 9.2 51.7 ± 10.2        \>1000 (n = 70) \>1000 (n = 31)       97 237                  ---/---/77 ---/---/182    \>5 (n = 49) \>5 (n = 101)   1-3,5-10,12,14        16                 19
  Lee \[[@B38]\]         2009       2000-2006              Taiwan         TACE (+) TACE (−)   114 236               89/25 173/63   57.9 ± 11.3 57.8 ± 11.7       2265.88 ± 8438.55 1862.52 ± 1388.63   110/4/0 232/4/0         ---/---/79 ---/---/152    4.3 ± 3.1 3.9 ± 2.7          1-3,5,7-10, 12,15     11                 18
  Kang \[[@B39]\]        2010       1997-2007              Korea          TACE (+) TACE (−)   32 64                 25/7 51/13     52.4 ± 9.8 54.0 ± 10.8        9584.4 ± 26238.5 5100.9 ± 24773.9     30/2/0 64/0/0           ---/---/--- ---/---/---   4.3 ± 2.5 4.5 ± 3.2          1-3,5,6,9,10,15       ---                20
  Yamashita \[[@B40]\]   2012       1995-2008              Japan          TACE (+) TACE (−)   42 95                 36/7 77/18     58 ± 12 64 ± 9                1527 ± 4415 1125 ± 4713               31/---/--- 88/---/---   ---/---/7 ---/---/26      9.1 ± 3.2 7.9 ± 3.0          2-4,7-11              1,5,6              20

LB liver background; N/H/C normal/hepatitis/cirrhosis; 1, Age; 2, Gender; 3, AFP level; 4, ICG R15 (%); 5, Child-Pugh grade; 6, Viral status; 7, Operative procedures; 8, LB; 9, Tumor size; 10 Tumor number;11, Histologic grade; 12,Vascular invasion; 13, Tumor encapsulation; 14, Intrahepatic metastasis or satellite nodules; 15, Pathological stage; 16,Capsular invasion;17, Adjacent organ invasion.

The data regarding the effects of TACE on tumor responses were available in 18 studies \[[@B10]-[@B16],[@B24],[@B28],[@B30]-[@B38]\], in which histological examination on surgical specimens revealed that a total of 260 patients (20.1%) of 1,292 patients had complete tumor necrosis ranging from 0 to 53.6%.

The funnel plot (Figure [1](#F1){ref-type="fig"}) for 5-year disease-free survival in the included studies demonstrated asymmetry, indicating an insignificant sign of publication bias.

![**Funnel plot analysis of publication bias.** The outcome was the 5-year disease-free survival.](1471-230X-13-51-1){#F1}

Overall meta-analysis
---------------------

The results from overall meta-analysis are summarized in Table [2](#T2){ref-type="table"}.

###### 

Results of overall meta-analysis

  **Outcomes**                    **No. of studies**                                                                       **No.of patients**   **Results**   **OR (95% CI)**   ***P*value**   **HG*p*value**             
  ------------------------------- ---------------------------------------------------------------------------------------- -------------------- ------------- ----------------- -------------- ------------------- ------ --------
  **Long-term outcomes**                                                                                                                                                                                                   
  5-years disease-free survival   18\[[@B10],[@B11],[@B13]-[@B16],[@B24],[@B28],[@B31]-[@B40]\]                            1275                 1567          32.1%             30.0%          1.19 (0.93, 1.53)   0.17   0.02
  5-years overall survival        16\[[@B11],[@B12],[@B14]-[@B16],[@B24],[@B28],[@B29],[@B31],[@B34]-[@B40]\]              1038                 1463          40.2%             45.2%          0.85 (0.59, 1.22)   0.37   \<0.01
  Total recurrence                11\[[@B10],[@B14],[@B16],[@B24],[@B30],[@B32],[@B35],[@B36]\],\[[@B38]-[@B40]\]          673                  917           61.0%             58.4%          0.99 (0.72, 1.36)   0.95   0.08
  Intrahepatic recurrence         12\[[@B10]-[@B12],[@B14],[@B16],[@B24],[@B29],[@B30],[@B32],[@B35]\],\[[@B36],[@B39]\]   660                  797           51.2%             53.6%          0.84 (0.67, 1.05)   0.12   0.23
  Extrahepatic recurrence         9\[[@B10],[@B14],[@B16],[@B24],[@B30],[@B32],[@B35],[@B36]\],\[[@B39]\]                  519                  591           12.9%             10.3%          1.30 (0.88, 1.92)   0.19   0.33
  **Short-term outcomes**                                                                                                                                                                                                  
  Overall morbidity               11\[[@B10]-[@B12],[@B14],[@B16],[@B24],[@B29],[@B30],[@B35],[@B36]\],\[[@B40]\]          583                  803           28.9%             26.8%          1.02 (0.80, 1.32)   0.85   0.42
  Liver failure                   6\[[@B11],[@B12],[@B14],[@B16],[@B29],[@B36]\]                                           337                  457           5.9%              6.3%           1.06 (0.57, 1.96)   0.86   0.31
  Bile leakage                    6\[[@B12],[@B14],[@B16],[@B29],[@B35],[@B36]\]                                           371                  569           3.5%              2.8%           1.12 (0.53, 2.35)   0.77   0.80
  Pleural effusion                4\[[@B12],[@B29],[@B35],[@B36]\]                                                         300                  485           7.0%              8.0%           0.93 (0.53, 1.65)   0.24   0.26
  Ascites                         3\[[@B29],[@B35],[@B36]\]                                                                269                  378           6.3%              6.1%           0.98 (0.51, 1.89)   0.96   0.16
  Intra-abdominal abscess         5\[[@B11],[@B14],[@B29],[@B35],[@B36]\]                                                  348                  451           2.5%              1.3%           1.66 (0.63, 4.40)   0.31   0.58
  Wound infection                 5\[[@B12],[@B14],[@B16],[@B35],[@B36]\]                                                  311                  501           3.2%              2.5%           1.11 (0.48, 2.53)   0.81   0.35
  Postoperative bleeding          3\[[@B11],[@B12],[@B36]\]                                                                206                  305           3.3%              2.9%           1.25 (0.41, 3.81)   0.69   0.63
  Stress ulcer bleeding           3\[[@B12],[@B29],[@B35]\]                                                                180                  332           1.1%              1.2%           1.31 (0.29, 5.92)   0.73   0.74
  Pneumonia                       4\[[@B11],[@B12],[@B14],[@B35]\]                                                         199                  337           4.0%              2.1%           1.64 (0.60, 4.46)   0.33   0.23
  Mortality                       16\[[@B10]-[@B12],[@B14]-[@B16],[@B24],[@B28]-[@B30],[@B33]-[@B36],[@B38],[@B40]\]       1100                 1325          4.1%              3.1%           1.25 (0.80, 1.97)   0.33   0.85

HG heterogeneity.

Long-term outcomes
------------------

The 5-year disease-free survival was 7.0--57% for preoperative TACE and 8.0--48.8% for control in 18 studies \[[@B10],[@B11],[@B13]-[@B16],[@B24],[@B28],[@B31]-[@B40]\]. The 5-year overall survival was 15.4--62.7% for preoperative TACE and 19.0--62.5% for control in 16 studies \[[@B11],[@B12],[@B14]-[@B16],[@B24],[@B28],[@B29],[@B31],[@B34]-[@B40]\]. Pooled analyses showed that preoperative TACE use was not associated with significant improvement in disease-free and 5-year overall survival (32.1% vs. 30.0%, *P* = 0.17; 40.2% vs. 45.2%, *P* = 0.37, respectively). There was significant heterogeneity between studies reporting these two outcomes (*P* = 0.02, *P* \< 0.01; respectively) (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

![Results of the meta-analysis on 5-year disease-free survival.](1471-230X-13-51-2){#F2}

![Results of the meta-analysis on 5-year overall survival.](1471-230X-13-51-3){#F3}

Eleven studies reported on total recurrence after surgery: 411 61.0%) of 673 with preoperative TACE vs.536 (58.4%) of 917 without TACE \[[@B10],[@B14],[@B16],[@B24],[@B30],[@B32],[@B35],[@B36]\],\[[@B38]-[@B40]\]. Pooled analyses showed that the difference was insignificant between the two groups (*P* = 0.95). There was moderate heterogeneity between studies (*P* = 0.08).

Further pooled analysis of studies providing information found that the percentages of both intra- and extrahepatic recurrence were also similar in the two groups (51.2% vs.53.6%, *P* = 0.12; 12.9% vs. 10.3%, *P* = 0.19, respectively). No significant heterogeneity was detected between the groups in reporting these two outcomes (Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}).

![Results of the meta-analysis on intrahepatic recurrence.](1471-230X-13-51-4){#F4}

![Results of the meta-analysis on extrahepatic recurrence.](1471-230X-13-51-5){#F5}

Short-term outcomes
-------------------

Eleven studies reported on overall morbidity: 169 (28.9%) of 583 with preoperative TACE vs. 216 (26.8%) of 803 without TACE \[[@B10]-[@B12],[@B14],[@B16],[@B24],[@B29],[@B30],[@B35],[@B36]\],\[[@B40]\]. Pooled analyses showed that the difference was insignificant between the two groups (*P* =0.85) without significant heterogeneity (Figure [6](#F6){ref-type="fig"}). Further subanalysis showed that the risk was comparable between patients in both study groups with respect to liver failure (5.9% vs. 6.3%, *P* =0.86), bile leakage (3.5% vs. 2.8%, *P* =0.77), pleural effusion (7.0% vs. 8.0%, *P* =0.24), ascites (6.3% vs. 6.1%, *P* =0.96), intra-abdominal abscess (2.5% vs. 1.3%, *P* =0.31), wound infection (3.2% vs. 2.5%, *P* =0.81), postoperative bleeding (3.3% vs. 2.9%, *P* =0.69), stress ulcer bleeding (1.1% vs. 1.2%, *P* =0.73), and pneumonia (4.0% vs. VS. 2.1%, *P* =0.33).

![Results of the meta-analysis on overall morbidity.](1471-230X-13-51-6){#F6}

Sixteen studies reported on in-hospital mortality \[[@B10]-[@B12],[@B14]-[@B16],[@B24],[@B28]-[@B30],[@B33]-[@B36],[@B38],[@B40]\], showing that 87 patients died: 46 in the preoperative TACE group and 41 in the control group. Pooled analyses showed that there was no statistical difference between the two groups (*P* =0.33) (Figure [7](#F7){ref-type="fig"}).

![Results of the meta-analysis on in-hospital mortality.](1471-230X-13-51-7){#F7}

Sensitivity analysis
--------------------

As Table [3](#T3){ref-type="table"} shows, the results of sensitivity analysis derived from three subgroups were all consistent with those derived from overall meta-analysis.

###### 

Results of sensitivity analysis

  **Outcome**                                                        **No. of studies**                                               **No.of patients**   **Results**  **OR (95% CI)**   ***P*value**   **HG*p*value**             
  ------------------------------------------------------------------ --------------------------------------------------------------- -------------------- ------------- ----------------- -------------- ------------------- ------ --------
  **RCTs**                                                                                                                                                                                                                           
  5-years disease-free survival                                      4\[[@B14]-[@B16],[@B24]\]                                               167               172      29.3%             31.9%          0.85 (0.53, 1.39)   0.52   0.16
  5-years overall survival                                           4\[[@B14]-[@B16],[@B24]\]                                               167               172      36.5%             38.3%          0.89 (0.56, 1.41)   0.61   0.11
  Total recurrence                                                   3\[[@B14],[@B16],[@B24]\]                                               116               124      74.1%             74.2%          1.03 (0.36, 2.90)   0.96   0.07
  Intrahepatic recurrence                                            3\[[@B14],[@B16],[@B24]\]                                               116               124      50.0%             46.7%          1.32 (0.47, 3.70)   0.59   0.02
  Extrahepatic recurrence                                            3\[[@B14],[@B16],[@B24]\]                                               116               124      28.4%             22.5%          1.37 (0.42, 4.43)   0.60   0.04
  Overall morbidity                                                  3\[[@B14],[@B16],[@B24]\]                                               113               127      20.3%             21.2%          0.97 (0.52, 1.82)   0.93   0.14
  Mortality                                                          4\[[@B14]-[@B16],[@B24]\]                                               163               174      3.1%              4.0%           0.70 (0.22, 2.30)   0.56   0.95
  **NRCTs**                                                                                                                                                                                                                          
  5-years disease-free survival                                      14\[[@B10],[@B11],[@B13],[@B28],[@B31]-[@B40]\]                         1108             1395      32.4%             29.8%          1.28 (0.98, 1.67)   0.07   0.04
  5-years overall survival                                           12\[[@B11],[@B12],[@B28],[@B29],[@B31],[@B34]-[@B40]\]                  871              1291      40.9%             46.1%          0.86 (0.55, 1.32)   0.48   \<0.01
  Total recurrence                                                   8\[[@B10],[@B30],[@B32],[@B35],[@B36],[@B38]-[@B40]\]                   559               795      58.1%             55.8%          0.98 (0.77, 1.25)   0.86   0.11
  Intrahepatic recurrence                                            9\[[@B10]-[@B12],[@B29],[@B30],[@B32],[@B35],[@B36],[@B39]\]            546               675      51.2%             56.5%          0.79 (0.62, 1.01)   0.06   0.84
  Extrahepatic recurrence                                            6\[[@B10],[@B30],[@B32],[@B35],[@B36],[@B39]\]                          403               467      8.4%              7.0%           1.22 (0.73, 2.06)   0.44   0.74
  Overall morbidity                                                  8\[[@B10]-[@B12],[@B29],[@B30],[@B35],[@B36],[@B40]\]                   470               676      31.0%             27.9%          1.03 (0.79, 1.36)   0.81   0.50
  Mortality                                                          12\[[@B10]-[@B12],[@B28]-[@B30],[@B33]-[@B36],[@B38],[@B40]\]           937              1151      4.3%              2.9%           1.39 (0.85, 2.28)   0.19   0.74
  **Studies with complete matched clinicopathological parameters**                                                                                                                                                                   
  5-years disease-free survival                                      6\[[@B15],[@B16],[@B28],[@B32],[@B35],[@B39]\]                          421               404      26.8%             22.0%          1.13 (0.62, 2.05)   0.69   0.02
  5-years overall survival                                           7\[[@B12],[@B15],[@B16],[@B28],[@B32],[@B35],[@B39]\]                   452               511      44.6%             35.2%          1.15 (0.76, 1.74)   0.50   0.08
  Total recurrence                                                   5\[[@B16],[@B30],[@B32],[@B35],[@B39]\]                                 297               349      73.7%             76.5%          0.91 (0.62, 1.33)   0.64   0.15
  Intrahepatic recurrence                                            6\[[@B12],[@B16],[@B30],[@B32],[@B35],[@B39]\]                          328               456      56.4%             60.1%          0.81 (0.59, 1.11)   0.20   0.69
  Extrahepatic recurrence                                            5\[[@B16],[@B30],[@B32],[@B35],[@B39]\]                                 297               349      13.1%             9.4%           1.40 (0.83, 2.38)   0.21   0.80
  Overall morbidity                                                  4\[[@B12],[@B16],[@B30],[@B35]\]                                        191               344      36.1%             28.2%          1.36 (0.91, 2.01)   0.13   0.48
  Mortality                                                          6\[[@B12],[@B15],[@B16],[@B28],[@B30],[@B35]\]                          339               423      4.4%              3.7%           1.16 (0.52, 2.57)   0.71   0.50

HG heterogeneity.

Discussion
==========

The design of TACE is based on the principle that primary HCC is supplied almost exclusively (90%) by the hepatic arteries. The obstruction of the feeding arteries can induce tumor ischemic necrosis. A combination of chemotherapy can drastically increase the local concentration of the chemotherapeutic agent and may improve the benefit of therapy. In 2003, a review of 7 RCTs showed that TACE significantly improved 2-year overall survival compared with nonactive treatment in patients with unresectable HCC \[[@B41]\]. In 2005, this therapy was recommended as standard intervention for unresectable patients with large/multifocal HCC who do not have vascular invasion or extrahepatic spread \[[@B7]\]. In contrast, the results of present pooled analysis of 21 trials do not support the use of preoperative TACE in the management of patients with resectable HCC.

Although TACE is effective for main tumors, intrahepatic metastases, tumor thrombi in the portal veins, and capsular invasion, which are considered risk factors contributing to HCC recurrence, are more unresponsive to TACE because of collateral and portal vein blood supply \[[@B8],[@B13],[@B16]\]. In addition, TACE mainly affects well-differentiated HCC without completely killing poorly differentiated cells \[[@B42]\], which harbour a high grade of malignancy and ready spread within the portal venous system \[[@B43]\]. Furthermore, hematogeneous and lymphatic spread dissemination of cancer cells can precede TACE treatment. It is therefore reasonable to conclude that TACE is unable to reduce the risk of postoperative recurrence, or confer a survival advantage.

Adachi *et al.*\[[@B13]\] and Harada *et al.*\[[@B28]\] reported that the TACE subgroup with complete tumor necrosis had a better survival rate than the group without TACE. This is partly due to residual confounding, because tumors with complete necrosis are strongly associated with favorable tumor-related factors, such as smaller tumor size and tumor encapsulation or less portal involvement. On the other hand, several other reports failed to make the same conclusion \[[@B15],[@B28],[@B30],[@B31]\]. It was found in the present study that approximately 20.1% of HCC tumors responded completely to TACE, suggesting that most of the HCC tumor cells were viable even when treated with TACE. The labeling index of proliferating cell nuclear antigen (a most widely used proliferation-associated marker) was significantly higher in the TACE group, indicating that residual HCC cells following preoperative TACE exhibit more aggressive behavior \[[@B44]\]. In support of this observation, Liou *et al.*\[[@B45]\] indicated that incomplete HCC necrosis after TACE (especially combined with necrotic area \>50% main tumor size) was associated with the development of lung metastasis that has a strong adverse impact on patient survival. Adachi *et al.*\[[@B13]\] and Kim *et al.*\[[@B37]\] found that subjects with partial tumor necrosis had the lowest disease-free survival rate among the TACE subgroups and tended to have a lower survival rate than the group without TACE. Zhou *et al.*\[[@B16]\] noted that five patients lost the chance of potentially curative liver resection because of progression of disease with metastases (n = 4) and liver failure (n = 1) during intervals between last TACE hepatic resection. The mechanism underlying accelerated tumor progression by TACE is unclear. Intratumoral necrosis was found to weaken the adhesive potential of the tumor and subsequently facilitate the release of cancer cells from the primary tumor and dislodgment into the bloodstream \[[@B46]\]. Xiao *et al.*\[[@B47]\] reported that mutated p53 could enhance the proliferation of HCC cells and suppress the apoptosis of HCC cells after TACE. In addition, vascular endothelial growth factor (VEGF), the most specific known angiogenic factor that plays a critical role in tumor growth, invasion, and metastasis, was up-regulated by tumor tissue ischemia and hypoxia after TACE \[[@B48]\].

In the present meta-analysis, in-hospital mortality did not differ significantly between TACE group patients and non-TACE group patients. However, Gerunda *et al.*\[[@B25]\] reported that three patients died of liver failure during 2--5 months after surgery in the TACE group. Sasaki *et al.*\[[@B34]\] and Uchida *et al.*\[[@B29]\] reported that late death due to liver failure was significantly higher in the TACE group than that in the non-TACE group. Uchida *et al.*\[[@B29]\] considered that hepatic function impairment induced by TACE could be repaired easily in the noncirrhotic liver, but hepatic function may gradually and progressively deteriorate due to TACE in some cirrhotic patients.

This study has several limitations. First, much of the evidence comes from NRCTs that could either exaggerate or underestimate the measured magnitude of effect size \[[@B20]\]. To minimize this effect, we limited the analysis to well-designed studies. As a matter of fact, the estimates from overall meta-analysis were consistent with those derived from RCTs, suggesting that the magnitude of the effect was not affected by the inclusion of NRCTs. Second, significant heterogeneity was present in some outcomes. Variability in the surgeon experience and the chemoembolization schedule may have introduced potential bias. In addition, clinicopathological factors associated with recurrence, such as hepatitis status, cirrhotic liver, and tumor staging, might be another source of potential heterogeneity. The use of random-effects models partially mitigates this concern. Third, although 21 studies involving more than 3,000 patients were enrolled for analysis, funnel plot analysis revealed the sign of publication bias. This may relate to the use of published English data only. Fourth, it is important to note that 18 of the 21 studies were from Asia. This may raise a question regarding the validity of the results and applicability to other areas. Finally, although some authors have reported the efficacy of preoperative TACE for patients with advanced HCC \[[@B33]\] and large HCC \[[@B31],[@B40]\], the results are not further estimable for subgroup analysis given the absence of data in this respect in the other studies.

Conclusions
===========

The updated meta-analysis represents the largest body of information currently available for assessing the role of preoperative TACE for HCC. This study demonstrates that preoperative TACE does not seem to improve the prognosis and therefore it should be prudent to recommend it as a preoperative routine procedure for resectable HCC.
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